Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare.

  title={Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare.},
  author={Robert I. Griffiths and Michelle Gleeson and Mark D. Danese and Anthony O'Hagan},
  journal={Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research},
  volume={15 5},
  • R. Griffiths, M. Gleeson, A. O'Hagan
  • Published 1 July 2012
  • Medicine
  • Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Figures and Tables from this paper

Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data
These analyses, based on real-world evidence, show that the introduction of rituximab into clinical practice has produced a substantial number of incremental life-years and the economic benefit of the life- years gained greatly exceeds the added costs of treatment.
The burden of hepatitis C to the United States Medicare system in 2009: Descriptive and economic characteristics
The costs of HCV to Medicare in 2009 were substantial and expected to increase over the next decade, and annual costs for patients with chronic infection only and DCC were higher than values used in many cost‐effectiveness analyses.
Calculating Total Health Service Utilisation and Costs from Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment
These linked datasets provide comprehensive primary and secondary care data for large numbers of patients, which allows stratification of outcomes and proves it is possible to derive input parameters appropriate for economic models and their distributions directly from the population of interest.
An economic analysis of sublobar resection versus thermal ablation for early-stage non-small-cell lung cancer.
Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients
The direct medical costs of newly-diagnosed, TMZ-treated GBM in commercially insured patients are substantial, with estimated total cumulative costs of $268,031.
Cost-Effectiveness of Second-Line Chemotherapy/Biologics among Elderly Metastatic Colon Cancer Patients
The estimated survival benefit of receiving second-line chemotherapy/biologics was about 4 months, which is consistent with evidence from clinical trials and associated with an ICER that exceeds the traditional threshold.
Transarterial chemoembolization treatment: association between multiple treatments, cumulative expenditures, and survival.
Comparative and Cost Effectiveness of Treatment Modalities for Hepatocellular Carcinoma in SEER-Medicare
For patients diagnosed with initial diagnosis of HCC, transplant was most effective in reducing mortality, followed by resection, liver directed, and radiation or chemotherapy, and liver directed therapy was more cost effective than chemotherapy or radiation.
Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data.
Although first-line systemic anticancer treatment was generally consistent with guidelines (e.g., pemetrexed-platinum), poor patient outcomes highlight the need for effective treatment options for older patients with advanced MPM.
Methods for estimating costs in patients with hyperlipidemia experiencing their first cardiovascular event in the United Kingdom
Detailed costing using utilization data is feasible and representative of UK clinical practice, but is labor intensive; the availability of a standardized coding system in the UK drug costing data would greatly facilitate drug costing.


Estimating medical costs from incomplete follow-up data.
Extensive numerical studies show that the asymptotic approximations are adequate for practical use and the biases of the proposed estimators are small even when censoring may occur in the interiors of the intervals.
Estimating mean total costs in the presence of censoring
Although Carides’ regression method and Lin’s method with unknown cost histories were the best estimators of mean total costs across censoring mechanisms, the weighted cost method with known cost histories is the preferred method for obtaining an accurate estimate of the mean total cost alone and the uncertainty surrounding it.
Estimating lifetime or episode-of-illness costs under censoring.
This paper proposes a new estimator that extends the class of two-part models to deal with random right censoring and for continuous death and censoring times and is found to be unbiased and also more efficient for these designs.
Linear regression analysis of censored medical costs.
  • D. Lin
  • Mathematics
  • 2000
This paper deals with the problem of linear regression for medical cost data when some study subjects are not followed for the full duration of interest so that their total costs are unknown, and modified normal equations for the least-squares estimation are modified to properly account for the incompleteness of the data.
Estimating medical costs with censored data
Incompleteness of follow-up data is a common problem in estimating medical costs. Naive analysis using summary statistics on the collected data can result in severely misleading statistical
On estimators of medical costs with censored data.
On the equivalence of some medical cost estimators with censored data
The equivalence among various estimators that were introduced by Lin et al., Bang and Tsiatis, and Zhao and Tian is reported and conditions under which these estimators become identical and the biased estimators achieve consistency are identified.
Estimating medical care costs under conditions of censoring.
Cost of care for elderly cancer patients in the United States.
Net costs of care for elderly cancer patients in the United States for the 18 most prevalent cancers and for all other tumor sites combined are estimated and vary by tumor site, phase of care, stage at diagnosis, survival, and survival.